Start/BMY

Public research page

Market data comes from the live feed. The company research below uses verified public sources, but it is not a real-time personalized AI conclusion.

Analyze BMY in workspace
BMYNYSE/health care

Bristol-Myers Squibb Company

$59.34Up+1,76 (+3,06%)
Research reviewed: 12. Juli 2026, 00:00 UTC
Research overview3-month price contextInvestment thesisKey catalystsLatest earnings researchRecent newsData and research sources

Research overview

Bristol-Myers Squibb Company operates in Pharmaceuticals within the health care sector. This profile tracks its company-specific earnings drivers, valuation conditions, and primary-source risks.

Eröffnung
57,90
Hoch
59,44
Tief
57,54
Marktkapitalisierung
121,18 Mrd.
KGV
16.62
52-Wochen-Hoch
--
Dividende
4.380%
Quartalsdividende
--

3-month price context

Das Chart zeigt den jüngsten 3-Monats-Trend, damit Nutzer die kurzfristige Struktur verstehen können, bevor sie den vollen Workspace öffnen.

Investment thesis

Base case
Opdivo, Camzyos, Sotyktu, Breyanzi and Reblozyl can offset part of the mature-brand decline. The base case remains conditional on loss of exclusivity staying manageable.
Bull case
Opdivo, Camzyos, Sotyktu, Breyanzi and Reblozyl can offset part of the mature-brand decline. Improved manufacturing and site expansion can increase patient throughput for Breyanzi and Abecma. Clinical and regulatory milestones can refresh the portfolio across oncology, immunology and neuroscience.
Bear case
Generic and biosimilar competition can accelerate declines in major legacy products. Clinical setbacks or slow launches could leave growth products unable to replace lost legacy revenue. Acquisition-related debt can constrain flexibility while integration and milestone payments consume cash.

Key catalysts

  • Growth portfolio

    Opdivo, Camzyos, Sotyktu, Breyanzi and Reblozyl can offset part of the mature-brand decline.

  • Cell-therapy capacity

    Improved manufacturing and site expansion can increase patient throughput for Breyanzi and Abecma.

  • Late-stage pipeline

    Clinical and regulatory milestones can refresh the portfolio across oncology, immunology and neuroscience.

Principal risks

  • Loss of exclusivity

    Generic and biosimilar competition can accelerate declines in major legacy products.

  • Pipeline replacement risk

    Clinical setbacks or slow launches could leave growth products unable to replace lost legacy revenue.

  • Leverage and capital allocation

    Acquisition-related debt can constrain flexibility while integration and milestone payments consume cash.

Latest earnings research

Q1 2026

Bristol Myers Squibb's first-quarter 2026 update centered on growth-portfolio execution across oncology, hematology, immunology and cardiovascular products while legacy-product erosion and pipeline delivery remained central to the outlook.

Valuation interpretation

  • The valuation hinges on whether the growth portfolio can bridge a concentrated period of legacy-product exclusivity losses.
  • Pipeline value should be discounted for launch execution, clinical attrition and acquisition-related leverage.

Peer research

JNJLLYMRK

Recent news

Trefis · vor 8 Stunden

Own Regeneron For Biotech Growth? Incyte Is Making Its Case.

Zacks · vor 13 Stunden

Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks

BioPharma Dive · vor 14 Stunden

Agenus surges on study pivot; Apnimed lines up an IPO

Zacks · vor 3 Tagen

Will Myqorzo Drive Cytokinetics Higher Despite Competitive Pressure?

MT Newswires · vor 3 Tagen

Pfizer Poised for Mixed Second Quarter, RBC Says

Continue in the research workspace

Keep BMY in context, run a multi-agent analysis, and monitor thesis changes.

Analyze BMY free

Das gesamte Research-System erkunden

Jede Phase erfüllt eine klare Aufgabe und hinterlässt ein prüfbares Ergebnis.

AnalysemethodikMarktberichte lesen
Thesis invalidation
Reassess the thesis if generic and biosimilar competition can accelerate declines in major legacy products.

Simply Wall St. · vor 4 Tagen

Is Bristol-Myers Squibb (BMY) Cheap As Index Changes Reshape Investor Exposure?

Data and research sources

Research updated: 12. Juli 2026, 00:00 UTC
3 verified sources
Bristol Myers Squibb Reports First Quarter 2026 Financial ResultsBristol-Myers Squibb Company · earningsVerified

Fetched: 12.7.2026, 0:00:00 UTC

Published: 23.4.2026, 00:00:00

Open original source
Bristol-Myers Squibb Company Investor RelationsBristol-Myers Squibb Company · companyVerified

Fetched: 12.7.2026, 0:00:00 UTC

Open original source
Bristol Myers Squibb SEC filings and company factsU.S. Securities and Exchange Commission · filingVerified

Fetched: 12.7.2026, 0:00:00 UTC

Published: 23.4.2026, 00:00:00

Open original source
Aktien erkunden

Continue researching this stock

Marktanalyst

Marktanalyst fokussiert sich innerhalb von Kernresearch auf die Phase Beobachten und bereitet den Kontext für nachgelagerte Rollen vor.

Fundamentalanalyst

Fundamentalanalyst fokussiert sich innerhalb von Kernresearch auf die Phase Beobachten und bereitet den Kontext für nachgelagerte Rollen vor.

Nachrichtenanalyst

Nachrichtenanalyst fokussiert sich innerhalb von Kernresearch auf die Phase Beobachten und bereitet den Kontext für nachgelagerte Rollen vor.

Risikomanager

Risikomanager fokussiert sich innerhalb von Risiko und Monitoring auf die Phase Überwachen und bereitet den Kontext für nachgelagerte Rollen vor.